Insider at Oncology Institute (TOI) adds 12,000 common shares

Rhea-AI Filing Summary

Chernett Jorey, a ten percent owner of Oncology Institute, Inc., reported an open-market purchase of 12,000 shares of Common Stock on June 4, 2026 at $4.75 per share. Following this transaction, Jorey directly holds 10,579,858 shares of Oncology Institute common stock.

Insider Trade Summary

Net Buyer: 12,000 shares ($57,000)

Net Buy 1 txn

Insider Chernett Jorey

Role null

Bought 12,000 shs ($57K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,000	$4.75	$57K

Holdings After Transaction: Common Stock — 10,579,858 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 12,000 shares Purchase price: $4.75 per share Shares owned after: 10,579,858 shares +1 more

4 metrics

Shares purchased 12,000 shares Open-market purchase of Common Stock on June 4, 2026

Purchase price $4.75 per share Price for the 12,000-share open-market transaction

Shares owned after 10,579,858 shares Total direct Common Stock holdings after the transaction

Net buy shares 12,000 shares Net buy direction per transactionSummary (net-buy)

Key Terms

Common Stock, open-market purchase, Form 4, ten percent owner

4 terms

Common Stock financial

"security_title: Common Stock in the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market purchase financial

"transaction_action: open-market purchase of 12,000 shares"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 regulatory

"Insider transaction was disclosed in a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

ten percent owner regulatory

"reporting person is flagged as is_ten_percent_owner: 1"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chernett Jorey

(Last) (First) (Middle)

6222 INDIANWOOD TR.

(Street)

BLOOMFIELD HILLS MICHIGAN 48301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		P		12,000	A	$4.75	10,579,858	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jorey Chernett	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TOI report on this Form 4?

Oncology Institute, Inc. reported a Form 4 insider purchase. Ten percent owner Chernett Jorey bought 12,000 shares of Common Stock in an open-market transaction on June 4, 2026, as disclosed in the filing.

How many TOI shares did Chernett Jorey buy and at what price?

Chernett Jorey purchased 12,000 TOI shares. The transaction was an open-market purchase of Common Stock at a price of $4.75 per share, according to the reported Form 4 data.

What are Chernett Jorey’s TOI holdings after this transaction?

After the transaction, Jorey holds 10,579,858 TOI shares. The Form 4 shows this total direct ownership of Oncology Institute Common Stock following the 12,000-share open-market purchase on June 4, 2026.

Was the TOI insider transaction a buy or sell?

The TOI insider transaction was a buy. The Form 4 classifies it as an open-market purchase, code “P,” with 12,000 shares of Common Stock acquired at $4.75 per share by ten percent owner Chernett Jorey.

Is the TOI Form 4 transaction a derivative or common stock trade?

The reported TOI transaction involves Common Stock, not derivatives. The Form 4 lists a non-derivative open-market purchase of 12,000 shares of Common Stock, with no accompanying derivative positions disclosed in the derivative summary.